
Biomarker Market Forecasts to 2030 – Global Analysis By Product (Consumables, Software and Services), Type (Safety Biomarkers, Validation Biomarkers and Efficacy Biomarkers), Indication, Service, Application, End User and By Geography
Description
Biomarker Market Forecasts to 2030 – Global Analysis By Product (Consumables, Software and Services), Type (Safety Biomarkers, Validation Biomarkers and Efficacy Biomarkers), Indication, Service, Application, End User and By Geography
According to Stratistics MRC, the Global Biomarker Market is accounted for $58.12 billion in 2023 and is expected to reach $110.24 billion by 2030 growing at a CAGR of 14.2% during the forecast period. A biomarker, short for biological marker, refers to a measurable and quantifiable biological parameter or characteristic that serves as an indicator of a physiological or pathological process, a disease state, or a response to treatment. Biomarkers can be found in various biological samples, such as blood, urine, tissue, or other bodily fluids. Biomarkers can encompass a wide range of attributes, including genetic mutations, gene expression patterns, protein levels, enzyme activity, metabolite concentrations, and imaging features.
According to data published by ministry of health in China, about 203 million people are suffering from cardiovascular diseases and this number is expected to increase by 73% in 2030.
Market Dynamics
Driver
Increase in cancer incidence
Cancer is a complicated illness caused by a multi-stage carcinogenesis process with several molecular pathway events that make diagnosis, prognosis, and treatment difficult. A single marker is ineffective because cancer is complicated. Additionally, each kind of cancer has a unique molecular profile from the others. The identification of novel biomarkers opens up new avenues for the development of treatment approaches intended to correct dysregulation in cancer. As a result, the worldwide market will expand due to the development of biomarker research and the rising incidence of cancer.
Restraint
Strict regulations
Strict rules and regulations are imposed to help build confidence and trust among healthcare providers, patients, and stakeholders in the biomarker market. This is crucial for the widespread adoption of biomarker-based diagnostics and therapies. Regulations promote standardization in the development, validation, and application of biomarkers. These regulations are complex and therefore become critical for making uninformed medical decisions. Thereby, this element hampers the market growth.
Opportunity
Rising popularity of personalized medicine
Personalized medicine relies on biomarkers to identify specific genetic, molecular, or biochemical characteristics of a patient's disease. These biomarkers help determine the most effective treatment options, minimizing the need for trial-and-error approaches. By tailoring treatments to the individual patient's biological makeup, personalized medicine aims to increase treatment efficacy. Personalized medicine, guided by biomarkers, allows for the customization of drug dosage and treatment regimens based on individual patient characteristics, optimizing therapeutic outcomes. Its greater patient engagement and satisfaction followed up by early disease detection and prevention fuels the market growth.
Threat
High development costs
The development of biomarkers requires significant financial investment and a multidisciplinary approach involving scientists, clinicians, regulatory experts, and other professionals. The high development costs reflect the complexity and rigor required to bring reliable biomarkers to clinical practice. Also, biomarker development often involves long and iterative processes; this prolonged timeline can result in cumulative costs. In addition, maintaining high standards of quality, recruiting skilled scientists and setting up technological infrastructure adds extra expenses which hinder the market demand.
Covid-19 Impact
The COVID-19 pandemic has a moderately beneficial effect on the biomarkers industry since biomarkers are essential for the creation of COVID-19 patient therapeutics. Biomarkers were discovered to be essential in the diagnosis and therapy in a number of studies. In addition, several organisations have introduced biomarker products to identify and treat COVID-19. These developments caused the market to expand throughout the pandemic era.
The cancer segment is expected to be the largest during the forecast period
The cancer segment is estimated to have a lucrative growth. Biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They are measurable biological indicators that can provide information about the presence or progression of cancer, as well as the likely response to specific treatments. It can help identify specific molecular or genetic characteristics of a tumor, allowing for the selection of targeted therapies that are more likely to be effective. From early detection to treatment selection, monitoring and research, biomarker contributes to more personalized and effective approaches to cancer diagnosis and treatment.
The diagnostics & research laboratories segment is expected to have the highest CAGR during the forecast period
The diagnostics & research laboratories segment is anticipated to witness the highest CAGR growth during the forecast period. Diagnostic labs play a vital role in monitoring disease progression and evaluating the effectiveness of treatments. Diagnostics and research laboratories play a pivotal role in advancing the field of biomarkers. They are involved in every stage of the biomarker development and application process, from discovery and validation to clinical testing, assay development, and patient care. Their work contributes significantly to improving disease diagnosis, treatment selection, and patient outcomes.
Region with largest share
North America is projected to hold the largest market share during the forecast period owing to the high disease burden, rising consumer awareness of biomarkers, encouraging government efforts, technical breakthroughs, and improvements in healthcare infrastructure. In North America, the United States holds the largest market share. A significant element anticipated to fuel the region's growth is the presence of prominent firms in this area and the many organic and inorganic projects they have undertaken.
Region with highest CAGR
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to its high prevalence of cancer, rising research initiatives, and low cost of clinical trials. Application of biomarkers in the drug discovery and development process is boosting key market players to invest in the research to develop novel biomarkers. In addition, an increase in funding for biotech and pharma companies, a rise in the number of CROs, and an increasing application scope of biomarkers are expected to facilitate regional market growth during the projected period.
Key players in the market
Some of the key players profiled in the Biomarker Market include GE Healthcare, Aushon Biosystem, Eisai Co. Limited, Abbott Laboratories, Inc., Epistem Limited, Agilent Technologies Inc., Roche Diagnostics Limited, Siemens AG, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., Johnson & Johnson Services, Inc., Epigenomics AG, QIAGEN, Enzo Biochem Inc, Charles River Laboratories International Inc., Eurofins Scientific, LifeSign LLC, Bruker, Sino Biological Inc and Quest Diagnostics Incorporated.
Key Developments
In November 2022, Siemens is expanding its generator circuit-breaker portfolio with a new compact version - the HB1-Compact (HB1-C). The versatile and highly customizable solution uses maintenance-free vacuum switching technology and addresses the most challenging of constraints.
In September 2022, GE Healthcare, a medical technology, diagnostics, and digital solutions company, launched its ‘Made in India’, ‘AI-powered’ Cath lab-Optima IGS 320 to advance cardiac care in India. It is built at Wipro GE Healthcare’s new Bengaluru factory and leverages the GE proprietary AutoRight technology.
Products Covered
• Consumables
• Software
• Services
Types Covered
• Safety Biomarkers
• Validation Biomarkers
• Efficacy Biomarkers
Indications Covered
• Cancer
• Cardiovascular Disorders
• Infectious Diseases
• Neurological Disorders
• Immunological Disorders
• Other Indications
Services Covered
• Assay Development
• Biomarker Validation & Testing
• Sample Preparation
• Other Services
Applications Covered
• Drug Discovery & Development
• Disease Diagnostics
• DNA Fingerprinting
• Personalized Medicine
• Disease Risk Assessment
• Other Applications
End Users Covered
• Pharmaceutical & Biotechnology Companies
• Hospitals & Specialty Clinics
• Diagnostics & Research Laboratories
• Other End Users
Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Table of Contents
200 Pages
- 1 Executive Summary
- 2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
- 3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Application Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19
- 4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
- 5 Global Biomarker Market, By Product
- 5.1 Introduction
- 5.2 Consumables
- 5.3 Software
- 5.4 Services
- 6 Global Biomarker Market, By Type
- 6.1 Introduction
- 6.2 Safety Biomarkers
- 6.3 Validation Biomarkers
- 6.4 Efficacy Biomarkers
- 6.4.1 Predictive Biomarkers
- 6.4.2 Surrogate Biomarkers
- 6.4.3 Pharmacodynamic Biomarkers
- 6.4.4 Prognostic Biomarkers
- 7 Global Biomarker Market, By Indication
- 7.1 Introduction
- 7.2 Cancer
- 7.3 Cardiovascular Disorders
- 7.4 Infectious Diseases
- 7.5 Neurological Disorders
- 7.6 Immunological Disorders
- 7.7 Other Indications
- 8 Global Biomarker Market, By Service
- 8.1 Introduction
- 8.2 Assay Development
- 8.3 Biomarker Validation & Testing
- 8.4 Sample Preparation
- 8.5 Other Services
- 9 Global Biomarker Market, By Application
- 9.1 Introduction
- 9.2 Drug Discovery & Development
- 9.3 Disease Diagnostics
- 9.3.1 Oncology
- 9.3.2 Neurology
- 9.3.3 Cardiology
- 9.4 DNA Fingerprinting
- 9.5 Personalized Medicine
- 9.6 Disease Risk Assessment
- 9.7 Other Applications
- 10 Global Biomarker Market, By End User
- 10.1 Introduction
- 10.2 Pharmaceutical & Biotechnology Companies
- 10.3 Hospitals & Specialty Clinics
- 10.4 Diagnostics & Research Laboratories
- 10.5 Other End Users
- 11 Global Biomarker Market, By Geography
- 11.1 Introduction
- 11.2 North America
- 11.2.1 US
- 11.2.2 Canada
- 11.2.3 Mexico
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 Italy
- 11.3.4 France
- 11.3.5 Spain
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 New Zealand
- 11.4.6 South Korea
- 11.4.7 Rest of Asia Pacific
- 11.5 South America
- 11.5.1 Argentina
- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
- 11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 UAE
- 11.6.3 Qatar
- 11.6.4 South Africa
- 11.6.5 Rest of Middle East & Africa
- 12 Key Developments
- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies
- 13 Company Profiling
- 13.1 GE Healthcare
- 13.2 Aushon Biosystem
- 13.3 Eisai Co. Limited
- 13.4 Abbott Laboratories, Inc.
- 13.5 Epistem Limited
- 13.6 Agilent Technologies Inc.
- 13.7 Roche Diagnostics Limited
- 13.8 Siemens AG
- 13.9 Bio-Rad Laboratories
- 13.10 Thermo Fisher Scientific Inc.
- 13.11 Johnson & Johnson Services, Inc.
- 13.12 Epigenomics AG
- 13.13 QIAGEN
- 13.14 Enzo Biochem Inc
- 13.15 Charles River Laboratories International Inc.
- 13.16 Eurofins Scientific
- 13.17 LifeSign LLC
- 13.18 Bruker
- 13.19 Sino Biological Inc
- 13.20 Quest Diagnostics Incorporated
- List of Tables
- Table 1 Global Biomarker Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Biomarker Market Outlook, By Type (2021-2030) ($MN)
- Table 3 Global Biomarker Market Outlook, By Safety Biomarkers (2021-2030) ($MN)
- Table 4 Global Biomarker Market Outlook, By Validation Biomarkers (2021-2030) ($MN)
- Table 5 Global Biomarker Market Outlook, By Efficacy Biomarkers (2021-2030) ($MN)
- Table 6 Global Biomarker Market Outlook, By Predictive Biomarkers (2021-2030) ($MN)
- Table 7 Global Biomarker Market Outlook, By Surrogate Biomarkers (2021-2030) ($MN)
- Table 8 Global Biomarker Market Outlook, By Pharmacodynamic Biomarkers (2021-2030) ($MN)
- Table 9 Global Biomarker Market Outlook, By Prognostic Biomarkers (2021-2030) ($MN)
- Table 10 Global Biomarker Market Outlook, By Indication (2021-2030) ($MN)
- Table 11 Global Biomarker Market Outlook, By Cancer (2021-2030) ($MN)
- Table 12 Global Biomarker Market Outlook, By Cardiovascular Disorders (2021-2030) ($MN)
- Table 13 Global Biomarker Market Outlook, By Infectious Diseases (2021-2030) ($MN)
- Table 14 Global Biomarker Market Outlook, By Neurological Disorders (2021-2030) ($MN)
- Table 15 Global Biomarker Market Outlook, By Immunological Disorders (2021-2030) ($MN)
- Table 16 Global Biomarker Market Outlook, By Other Indications (2021-2030) ($MN)
- Table 17 Global Biomarker Market Outlook, By Service (2021-2030) ($MN)
- Table 18 Global Biomarker Market Outlook, By Assay Development (2021-2030) ($MN)
- Table 19 Global Biomarker Market Outlook, By Biomarker Validation & Testing (2021-2030) ($MN)
- Table 20 Global Biomarker Market Outlook, By Sample Preparation (2021-2030) ($MN)
- Table 21 Global Biomarker Market Outlook, By Other Services (2021-2030) ($MN)
- Table 22 Global Biomarker Market Outlook, By Application (2021-2030) ($MN)
- Table 23 Global Biomarker Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
- Table 24 Global Biomarker Market Outlook, By Disease Diagnostics (2021-2030) ($MN)
- Table 25 Global Biomarker Market Outlook, By Oncology (2021-2030) ($MN)
- Table 26 Global Biomarker Market Outlook, By Neurology (2021-2030) ($MN)
- Table 27 Global Biomarker Market Outlook, By Cardiology (2021-2030) ($MN)
- Table 28 Global Biomarker Market Outlook, By DNA Fingerprinting (2021-2030) ($MN)
- Table 29 Global Biomarker Market Outlook, By Personalized Medicine (2021-2030) ($MN)
- Table 30 Global Biomarker Market Outlook, By Disease Risk Assessment (2021-2030) ($MN)
- Table 31 Global Biomarker Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 32 Global Biomarker Market Outlook, By End User (2021-2030) ($MN)
- Table 33 Global Biomarker Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
- Table 34 Global Biomarker Market Outlook, By Hospitals & Specialty Clinics (2021-2030) ($MN)
- Table 35 Global Biomarker Market Outlook, By Diagnostics & Research Laboratories (2021-2030) ($MN)
- Table 36 Global Biomarker Market Outlook, By Other End Users (2021-2030) ($MN)
- Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.